Evidence map›Paper›PMID 31181062›Full record

ArticlePLoS genetics2019

Essential gene deletions producing gigantic bacteria.

Jeannie Bailey, Julie Cass, Joe Gasper, Ngoc-Diep Ngo, Paul Wiggins, Colin Manoil

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Protein overabundance is driven by growth robustness.bioRxiv : the preprint server for biology · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Ranking essential bacterial processes by speed of mutant death.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jeannie BaileyDepartment of Genome Sciences, University of Washington, Seattle, Washington, United States of America.
Julie CassDepartment of Physics, University of Washington, Seattle, Washington, United States of America.ORCID 0000-0001-9829-194X
Joe GasperDepartment of Genome Sciences, University of Washington, Seattle, Washington, United States of America.
Ngoc-Diep NgoDepartment of Genome Sciences, University of Washington, Seattle, Washington, United States of America.
Paul WigginsDepartment of Physics, University of Washington, Seattle, Washington, United States of America.
Colin ManoilDepartment of Genome Sciences, University of Washington, Seattle, Washington, United States of America.ORCID 0000-0001-6773-3434
University of Washington · US

Funding

Protein Interaction Technology CoreU19AI107775 · NIAID · UNIVERSITY OF WASHINGTON · PI BRITTNACHER, MITCHELL J · 2013 to 2017
$7.7M
NIAID NIH HHS U19 AI107775
6 · The paper itself

Abstract

To characterize the consequences of eliminating essential functions needed for peptidoglycan synthesis, we generated deletion mutations of Acinetobacter baylyi by natural transformation and visualized the resulting microcolonies of dead cells. We found that loss of genes required for peptidoglycan precursor synthesis or polymerization led to the formation of polymorphic giant cells with diameters that could exceed ten times normal. Treatment with antibiotics targeting early or late steps of peptidoglycan synthesis also produced giant cells. The giant cells eventually lysed, although they were partially stabilized by osmotic protection. Genome-scale transposon mutant screening (Tn-seq) identified mutations that blocked or accelerated giant cell formation. Among the mutations that blocked the process were those inactivating a function predicted to cleave murein glycan chains (the MltD murein lytic transglycosylase), suggesting that giant cell formation requires MltD hydrolysis of existing peptidoglycan. Among the mutations that accelerated giant cell formation after ß-lactam treatment were those inactivating an enzyme that produces unusual 3->3 peptide cross-links in peptidoglycan (the LdtG L,D-transpeptidase). The mutations may weaken the sacculus and make it more vulnerable to further disruption. Although the study focused on A. baylyi, we found that a pathogenic relative (A. baumannii) also produced giant cells with genetic dependencies overlapping those of A. baylyi. Overall, the analysis defines a genetic pathway for giant cell formation conserved in Acinetobacter species in which independent initiating branches converge to create the unusual cells.

Indexed as

AcinetobacterAnti-Bacterial AgentsCell CycleCell DivisionCell WallDNA Transposable ElementsEscherichia coliGene DeletionGenes, EssentialGenome, BacterialGlycosyltransferasesPeptidoglycanPeptidyl TransferasesSequence DeletionAnti-Bacterial AgentsDNA Transposable ElementsGlycosyltransferasesmurein transglycosylasePeptidoglycanPeptidyl Transferases

Identifiers

PMID31181062
PMCPMC6586353
OpenAlexW2951227991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.